Preclinical evidence suggests that PARP-2 plays a pivotal role in erythroid differentiation and its deletion leads to extravascular haemolytic anaemia suggesting that PARP inhibitors may impact haematopoiesis, which may explain the haematological AEs observed in these studies [32,33]. Here, PARP2 is linked to non-autoimmune hemolytic anemia.